Fused Omics Data Models Reveal Gut Microbiome Signatures Specific of Inactive Stage of Juvenile Idiopathic Arthritis in Pediatric Patients.
Non-VOCs
fused omics data
gut metabolome
gut microbiome
microbiomics
operational taxonomic units
volatile-organic compounds
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
06 Oct 2020
06 Oct 2020
Historique:
received:
14
09
2020
revised:
01
10
2020
accepted:
02
10
2020
entrez:
10
10
2020
pubmed:
11
10
2020
medline:
11
10
2020
Statut:
epublish
Résumé
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Herein, we evaluated the relationship between the gut microbiome (GM) and disease phenotype by an integrated omics fused approach. In a multicenter, observational cohort study, stools from Italian JIA patients were collected at baseline, active, and inactive disease stages, and their GM compared to healthy controls (CTRLs). The microbiota metabolome was analyzed to detect volatile- and non-volatile organic compounds (VOCs); the data were fused with operational taxonomic units (OTUs) from 16S RNA targeted-metagenomics and classified by chemometric models. Non-VOCs did not characterize JIA patients nor JIA activity stages compared to CTRLs. The core of VOCs, (Ethanol, Methyl-isobutyl-ketone, 2,6-Dimethyl-4-heptanone and Phenol) characterized patients at baseline and inactive disease stages, while the OTUs represented by Ruminococcaceae, Lachnospiraceae and Clostridiacea discriminated between JIA inactive stage and CTRLs. No differences were highlighted amongst JIA activity stages. Finally, the fused data discriminated inactive and baseline stages versus CTRLs, based on the contribution of the invariant core of VOCs while Ruminococcaceae concurred for the inactive stage versus CTRLs comparison. In conclusion, the GM signatures enabled to distinguish the inactive disease stage from CTRLs.
Identifiants
pubmed: 33036309
pii: microorganisms8101540
doi: 10.3390/microorganisms8101540
pmc: PMC7650812
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Exp Immunol. 2017 Mar;187(3):480-489
pubmed: 27861762
PLoS One. 2018 Dec 6;13(12):e0208171
pubmed: 30521551
Front Microbiol. 2016 Jul 11;7:1081
pubmed: 27462309
Arthritis Res Ther. 2014 Nov 30;16(6):486
pubmed: 25434931
Curr Rheumatol Rep. 2013 Mar;15(3):314
pubmed: 23378145
Front Microbiol. 2016 Oct 26;7:1703
pubmed: 27833598
Immunol Rev. 2020 Mar;294(1):9-26
pubmed: 31833578
Hepatology. 2017 Feb;65(2):451-464
pubmed: 27028797
Appl Biochem Biotechnol. 2012 Nov;168(6):1718-27
pubmed: 22971835
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36
pubmed: 21717596
Pediatr Rheumatol Online J. 2016 Sep 20;14(1):55
pubmed: 27650128
Microbiome. 2019 Jun 13;7(1):91
pubmed: 31196177
Bioinformatics. 2017 Sep 1;33(17):2774-2775
pubmed: 28481966
Eur J Clin Microbiol Infect Dis. 2016 Mar;35(3):363-70
pubmed: 26718942
Ann Rheum Dis. 2014 Jul;73(7):1380-3
pubmed: 24347571
Hepatology. 2013 Feb;57(2):601-9
pubmed: 23055155
Arthritis Rheumatol. 2019 Jun;71(6):1000-1010
pubmed: 30592383
World J Clin Cases. 2019 Sep 26;7(18):2734-2745
pubmed: 31616689
Metabolomics. 2012 Jun;8(Suppl 1):3-16
pubmed: 22593721
Arthritis Rheum. 2009 May 15;61(5):658-66
pubmed: 19405003